12964_2024_1667_MOESM1_ESM.docx (1.47 MB)
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
journal contribution
posted on 2024-06-13, 04:01 authored by Rafael Rosell, Eloisa Jantus-Lewintre, Peng Cao, Xueting Cai, Baojuan Xing, Masaoki Ito, Jose Luis Gomez-Vazquez, Mireia Marco-Jordán, Silvia Calabuig-Fariñas, Andrés Felipe Cardona, Jordi Codony-Servat, Jessica Gonzalez, Kevin València-Clua, Andrés Aguilar, Carlos Pedraz-Valdunciel, Zahra Dantes, Anisha Jain, S Chandan, Miguel Angel Molina-Vila, Oscar Arrieta, Macarena Ferrero, Carlos Camps, Maria González-CaoSupplementary Material 1
Funding
Fundación Científica Asociación Española Contra el Cáncer National Natural Science Foundation of China
History
Usage metrics
Categories
Keywords
xenograft mouse modelshown promising activityshort median progressioncolony formation assaysmet mrna expressionwestern blot analysisdensity lipoprotein receptorg12c selective inhibitorsmet mrna levelskras mrna expressionhepatocyte growth factorfree survival accordingmutant nsclc patientsmet inhibitor tepotinibh358 sotorasib resistantfree survivalmet ),mutant g12cg12c inhibitorsynergy analysishigh levelscognate receptoroverall survivalmek inhibitorvivo studiestime rttherapy basedsignificant differencesrna isolationresistant krasrelated proteinpotential antihgf ),hazard ratiocancer properties
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC